(Q37183820)

18 August 2017

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma (English)

1 reference

18 August 2017

16

Lynda Chin

1 reference

18 August 2017

13

Keith T Flaherty

1 reference

18 August 2017

14

Jennifer A Wargo

1 reference

18 August 2017

5

Timothy L Helms

1 reference

18 August 2017

Lawrence N Kwong

1

1 reference

18 August 2017

James C Costello

2

1 reference

18 August 2017

Huiyun Liu

3

1 reference

18 August 2017

Shan Jiang

4

1 reference

18 August 2017

Aliete E Langsdorf

6

1 reference

18 August 2017

David Jakubosky

7

1 reference

18 August 2017

Giannicola Genovese

8

1 reference

18 August 2017

Florian L Muller

9

1 reference

18 August 2017

Joseph H Jeong

10

1 reference

18 August 2017

Ryan P Bender

11

1 reference

18 August 2017

Gerald C Chu

12

1 reference

18 August 2017

James J Collins

15

1 reference

18 August 2017

language of work or name

English

0 references

publication date

16 September 2012

1 reference

18 August 2017

1 reference

18 August 2017

18

1 reference

18 August 2017

10

1 reference

18 August 2017

1503-1510

1 reference

https://scigraph.springernature.com/pub.10.1038/nm.2941

18 August 2017

0 references

cites work

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

NRAS mutation status is an independent prognostic factor in metastatic melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Molecular signatures database (MSigDB) 3.0.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Shared and separate functions of polo-like kinases and aurora kinases in cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Logic-based models for the analysis of cell signaling networks

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Hyperactive Ras in developmental disorders and cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Cyclin-dependent kinase pathways as targets for cancer treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

BRAF mutation predicts sensitivity to MEK inhibition

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Essential role for oncogenic Ras in tumour maintenance

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Bayesian network approach to cell signaling pathway modeling

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Role of the INK4a locus in tumor suppression and cell mortality.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3777533

Improved survival with MEK inhibition in BRAF-mutated melanoma

3 September 2018

1 reference

7 January 2021

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

1 reference

7 January 2021

Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL.

1 reference

7 January 2021

Transcriptional gene network inference from a massive dataset elucidates transcriptome organization and gene function.

1 reference

7 January 2021

Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors

1 reference

7 January 2021

Linear models and empirical bayes methods for assessing differential expression in microarray experiments

1 reference

7 January 2021

Exploration, normalization, and summaries of high density oligonucleotide array probe level data

1 reference

7 January 2021

Large-scale mapping and validation of Escherichia coli transcriptional regulation from a compendium of expression profiles

1 reference

7 January 2021

Node centrality in weighted networks: Generalizing degree and shortest paths

1 reference

7 January 2021

Identifiers

DOI

10.1038/NM.2941

1 reference

Dimensions Publication ID

18 August 2017

1014975189

0 references

Fatcat ID

release_coglhdjh2nhbbbldgcbs3bmm4y

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/coglhdjh2nhbbbldgcbs3bmm4y

24 November 2022

mapped directly with Wikidata item

1 reference

18 August 2017

PubMed publication ID

22983396

1 reference